The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Takeda’s OBLEAN Joins Aug. 22 Review List of PAFSC 1st Committee
August 19, 2013
- 30-Plus Companies Gain Approval for Livalo, Valtrex Generics towards December Listing
August 16, 2013
- Case of Chagas Disease Confirmed through Blood Donation Raises Concern Over Secondary Infection
August 16, 2013
- 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
- PMDA Meets All Targets for FY2012 with Exception of Time Spent by Applicants for Non-Priority Products
August 15, 2013
- Can Japan Become the Global Leader in Drug Discovery? New Vision for Pharmaceutical Industry Drops Company Categories Included in the Previous One
August 15, 2013
- PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
- MHLW Compiles Report on Expert Council on Future Cancer Research
August 14, 2013
- EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
- 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
- Japan NIH HQ to Orchestrate Allocation of 100 Billion Yen for R&D Budgets, Starting with FY2014 Requests
August 12, 2013
- 1st Committee on Drugs to Discuss Pediatric Indication for Kyowa Kirin’s Nesp
August 12, 2013
- MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
- MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
- PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
- US FDA Advisory Committee Votes Against Approval of Tolvaptan for Treatment of ADPKD
August 8, 2013
- Education Ministry Set Up Task Force for Prevention of Misconduct in Research, Will Discuss Diovan Issue
August 7, 2013
- Gov’t to Establish “Headquarters to Promote Health and Healthcare Strategy” as HQ for Japanese Version of NIH
August 6, 2013
- First Committee on Drugs Recommends Approval for Long-Acting Injectable Schizophrenia Treatment Xeplion
August 6, 2013
- Health Ministry’s Diovan Study Committee to Start on Aug 9, Minister Expects Attendance of Ex-Novartis Employee
August 5, 2013
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…